Safety of a New Blood Thinner in AFib Patients
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have atrial fibrillation or flutter that needs long-term blood thinners (anticoagulation).
- Your CHA2DS2-VA score (a stroke risk calculator) must be at least 2—or 3 or more, or a score of 2 with extra risk factors.
- If you take warfarin or another vitamin K antagonist (like Coumadin), your INR blood test result must be below 2.5 at the time of joining.
- You cannot have a mechanical heart valve (but transcatheter aortic valve replacement is okay).
- You cannot have moderate to severe mitral stenosis (a narrowed heart valve).
- You cannot have had a stroke within 2 days before randomization, kidney function below a certain level (eGFR < 15), or a recent brain bleed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
This trial tests a new medication to prevent strokes and blood clots in people with atrial fibrillation (an irregular heartbeat) who cannot safely take standard blood thinners. The drug works by blocking a different clotting factor, which may lower bleeding risks.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
This trial tests whether a rhythm-guided approach to using blood thinners (antithrombotics) is safe and effective for people who have had both a heart stent and a successful ablation for atrial fibrillation. It may help you avoid unnecessary medication while preventing strokes and bleeds.
This study looks at stroke risk and blood clotting in people who have just been diagnosed with atrial fibrillation (AFib) that is not caused by a heart valve problem, and who have not yet taken blood thinners. It aims to better understand how blood clots form in this condition.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.